Hutchison China MediTech Ltd ADR buy stratec
Start price
06.03.18
/
50%
€31.57
Target price
06.03.19
€40.59
Performance (%)
-22.49%
End price
06.03.19
€24.47
Summary
This prediction ended on 06.03.19 with a price of €24.47. The prediction for Hutchison China MediTech Ltd ADR disappointed with a performance of -22.49%. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Hutchison China MediTech Ltd ADR | 9.783% | 9.783% | 56.589% | - |
| iShares Core DAX® | 2.749% | 4.620% | 17.121% | 21.210% |
| iShares Nasdaq 100 | 0.470% | -0.331% | 37.776% | 57.865% |
| iShares Nikkei 225® | -2.930% | -5.556% | 12.185% | 8.407% |
| iShares S&P 500 | 0.679% | 0.631% | 28.996% | 48.197% |
Comments by stratec for this prediction
In the thread Hutchison China MediTech Ltd ADR diskutieren
HCM with several data readouts coming could be catalysts for upside.
The stock offers investors a strong pipeline of differentiated candidates (up to 15 possible Breakthrough Therapy Designations), China exposure (via its sales team of over 3,200 employees and 1,900 medical professionals), validating partnerships and several upcoming catalysts. Downside appears limited due to having several irons in the fire, low cash burn as a result of its prescription drug commercial services segment offsetting clinical costs and quite a few pivotal readouts lined up over the next couple years.
(Laufzeit überschritten)